ImmPACT Bio has secured an $8m grant from the California Institute for Regenerative Medicine (CIRM) for its Phase Ib/II clinical trial of IMPT-514 to treat refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE).
A CD19/CD20-targeting bispecific chimeric antigen receptor (CAR) T-cell therapy, IMPT-514, is designed for autoreactive immune cell depletion.
Go deeper with GlobalData
The open-label dose escalation trial is designed to enrol participants with active, refractory SLE that was priorly treated with a minimum of two standard-of-care therapies previously.
Furthermore, these subjects should have a SLE Disease Activity Index score (SLEDAI-2K) greater than eight to be eligible for the trial.
The Phase I dose escalation segment specifically targets subjects who have active, biopsy-proven, proliferative LN.
During the subsequent Phase II portion of the clinical trial, additional patients, both with and without active proliferative LN, will be enrolled.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIMPT-514 was effectively produced from heavily immunosuppressed patients with LN and SLE in preclinical studies.
The therapy also demonstrated potent removal of autologous B cells and a moderate cytokine profile.
The US Food and Drug Administration (FDA) previously granted fast-track designation for the IMPT-514 treatment in active and refractory LN and SLE.
Notably, IMPT-514 shares the same CAR construct as another company asset, IMPT-314.
IMPT-314 is under development for certain types of non-Hodgkin’s lymphoma.
ImmPACT Bio chief medical officer Jonathan Benjamin said: “There is a critical unmet medical need for well-tolerated therapies that offer improved efficacy and durable disease remission.
“Based on the promising responses and a favourable safety profile observed in the UCLA trial in non-Hodgkin lymphoma, we are encouraged that IMPT-514 has the potential to alleviate symptoms and spare patients the need for chronic immune suppression.
“We expect initial efficacy and safety data from our Phase Ib/II dose escalation trial in the second half of 2024.”
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
